DFMO has a decades‐long history of safe administration in clinical trials and has recently been repurposed to treat patients with Bachmann–Bupp syndrome (BABS), a newly identified genetic disorder resulting from an ODC gain‐of‐function variant (Bupp et al, 2018; Rajasekaran et al, 2021). Here, ODC1 is linked to neurodevelopmental disorder with alopecia and brain abnormalities.